Model portefeuille
Rendement portefeulle
+12.035 %

Rendement AEX
+33.325 %

Startdatum
01-01-2009

Startwaarde portefeuille € 74082.37

Startwaarde AEX
€ 245.94


Laatste update:
29-01-2010

Second DuPont Microbiome partnership to focus on “next-generation” probiotics

Alleen voor leden beschikbaar, wordt daarom gratis lid!

14/03/2018 14:14
14 March 2018 --- A newly forged partnership between DuPont Nutrition & Health Microbiome Venture and the Center of Food and Fermentation Technologies (TFTAK) will aid strategic research and development of “next-generation” probiotics. This will mark DuPont Nutrition & Healthy Microbiome Venture’s second partnership in three months.

“We are delighted to be partnering with TFTAK. With its excellent capabilities in bioprocess technology and systems biology, TFTAK will support DuPont by defining the optimum conditions required to culture and produce some of our next-generation probiotic strain candidates,” says Microbiome Venture Leader Sebastien Guery.

Last November, DuPont Nutrition & Health announced the creation of its Microbiome Venture to spearhead the development of new microbiome science-based solutions. Since then, the Microbiome Venture has already taken significant steps in contributing to DuPont’s business growth strategy.

DuPont established the Microbiome Venture to accelerate microbiome science-based solution development through a combination of selected strategic partnerships with microbiome science leaders and internal investments.

“Our DuPont Nutrition & Health Microbiome Venture partnership will build on our long-term successful cooperation on the development and optimization of production processes for novel bacteria of interest to the dairy industry and potentially to nutrition, health and wellness companies more widely,” said Professor Raivo Vilu of TFTAK. “We are looking forward to an exciting next step in our cooperation.”

The Microbiome Venture is a team with a strong connection to the larger DuPont organization, tapping into capabilities including R&D, manufacturing, regulatory, legal and marketing. The Microbiome Venture investment will complement DuPont’s existing product portfolio, especially in the areas of probiotics and prebiotics, including human milk oligosaccharides (HMOs.)



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL